InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,471.05
(
1.16%
)
US TECH 100
18,167.36
(
-0.06%
)
Dow Jones
40,829.59
(
1.20%
)
Brent Oil
70.98
(
-1.02%
)
Bitcoin
57,131.66
(
0.19%
)
Post# of 253075
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: mcbio post# 133388

Wednesday, 01/11/2012 11:15:45 PM

Wednesday, January 11, 2012 11:15:45 PM

Post# of 253075
SLXP/(PGNX) @ JPM (1/11/12)

Starting just before the 22-minute mark of this presentation, as it relates to PGNX and Relistor, SLXP's CEO states that the current peak-year sales estimate for Relistor (she termed peak-year as being year 7) in its currently approved indication is about $50M. If they gain expanded approval in chronic patients, that peak estimate is $300-$350M. If SLXP/PGNX succeed in gaining approval for oral Relistor, that takes them to a "billion dollar opportunity."
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up